Alarming Rise in Breast and Cervical Cancers in Low- and Middle-Income Countries: Breaking Down Screening Barriers

By HEOR Staff Writer

July 5, 2023

Breast and cervical cancers are on the rise in low- and middle-income countries, with lower cure rates due to late diagnosis. Screening programs in these countries are not comprehensive, hindering early detection. 

By analysing studies published between 2016 and 2021, articles from low- and middle-income countries and using the 5A framework (approachability, acceptability, availability, affordability, and appropriateness), screening barriers were classified. 

Findings highlighted the lack of awareness, high screening costs, and distance to screening centers as major obstacles. Embarrassment, fear, and cultural factors also contribute to low screening rates. 

To combat these challenges, policymakers and governments must take action to enhance public confidence in healthcare systems. Evidence-based strategies are needed to educate women about cancer causes and risk factors, promoting increased adherence to screening. Together, we can make a difference in the fight against breast and cervical cancers worldwide.

Reference url

Recent Posts

NICE Approves Durvalumab for Gastric Cancer Treatment

By HEOR Staff Writer

May 15, 2026

NICE has issued final draft guidance recommending durvalumab, within its marketing authorisation, for use with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by durvalumab monotherapy as adjuvant treatment, in adults with ...
Bladder Cancer Treatment Impact: Barriers to Quality of Life in Patients
A global survey highlights the profound bladder cancer treatment impact on patients with non-muscle-invasive bladder cancer, with more than 90 percent of those undergoing radical cystectomy or BCG therapy reporting negative physical, emotional, and mental health effects. Life-Altering Effect...
Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at ASCO 2026

By HEOR Staff Writer

May 13, 2026

Merck oncology advancements continue to deliver meaningful progress for patients. New long-term data from multiple trials highlight sustained survival benefits across lung cancer, breast cancer, melanoma, and other tumor types. These advancements will feature prominently at the 2026 American S...